JP2018528389A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528389A5
JP2018528389A5 JP2017558949A JP2017558949A JP2018528389A5 JP 2018528389 A5 JP2018528389 A5 JP 2018528389A5 JP 2017558949 A JP2017558949 A JP 2017558949A JP 2017558949 A JP2017558949 A JP 2017558949A JP 2018528389 A5 JP2018528389 A5 JP 2018528389A5
Authority
JP
Japan
Prior art keywords
ligand
subunit
homodimer
seq
capillary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017558949A
Other languages
English (en)
Japanese (ja)
Other versions
JP7240812B2 (ja
JP2018528389A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/031899 external-priority patent/WO2016183222A1/en
Publication of JP2018528389A publication Critical patent/JP2018528389A/ja
Publication of JP2018528389A5 publication Critical patent/JP2018528389A5/ja
Priority to JP2021092988A priority Critical patent/JP7137663B2/ja
Priority to JP2022139802A priority patent/JP2022171730A/ja
Application granted granted Critical
Publication of JP7240812B2 publication Critical patent/JP7240812B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017558949A 2015-05-12 2016-05-11 多量体タンパク質の純度の決定 Active JP7240812B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021092988A JP7137663B2 (ja) 2015-05-12 2021-06-02 多量体タンパク質の純度の決定
JP2022139802A JP2022171730A (ja) 2015-05-12 2022-09-02 多量体タンパク質の純度の決定

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562160341P 2015-05-12 2015-05-12
US62/160,341 2015-05-12
PCT/US2016/031899 WO2016183222A1 (en) 2015-05-12 2016-05-11 Multimeric protein purity determination

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021092988A Division JP7137663B2 (ja) 2015-05-12 2021-06-02 多量体タンパク質の純度の決定

Publications (3)

Publication Number Publication Date
JP2018528389A JP2018528389A (ja) 2018-09-27
JP2018528389A5 true JP2018528389A5 (cg-RX-API-DMAC7.html) 2021-01-21
JP7240812B2 JP7240812B2 (ja) 2023-03-16

Family

ID=56072452

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017558949A Active JP7240812B2 (ja) 2015-05-12 2016-05-11 多量体タンパク質の純度の決定
JP2021092988A Expired - Fee Related JP7137663B2 (ja) 2015-05-12 2021-06-02 多量体タンパク質の純度の決定
JP2022139802A Pending JP2022171730A (ja) 2015-05-12 2022-09-02 多量体タンパク質の純度の決定

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021092988A Expired - Fee Related JP7137663B2 (ja) 2015-05-12 2021-06-02 多量体タンパク質の純度の決定
JP2022139802A Pending JP2022171730A (ja) 2015-05-12 2022-09-02 多量体タンパク質の純度の決定

Country Status (10)

Country Link
US (3) US10520511B2 (cg-RX-API-DMAC7.html)
EP (2) EP3294775B1 (cg-RX-API-DMAC7.html)
JP (3) JP7240812B2 (cg-RX-API-DMAC7.html)
AR (1) AR104610A1 (cg-RX-API-DMAC7.html)
AU (2) AU2016261854B2 (cg-RX-API-DMAC7.html)
CA (1) CA2984010A1 (cg-RX-API-DMAC7.html)
ES (1) ES2881359T3 (cg-RX-API-DMAC7.html)
MA (2) MA56416A (cg-RX-API-DMAC7.html)
PL (1) PL3294775T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016183222A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121253411A (zh) 2015-11-30 2026-01-02 因塔生物有限责任公司 用于样品表征的装置和方法
CN109937034B (zh) 2016-11-21 2022-09-16 济世-伊沃泰克生物制品有限公司 阿柏西普制剂及其用途
MY199833A (en) 2017-08-17 2023-11-24 Just Evotec Biologics Inc Method of purifying glycosylated protein from host cell galectins and other contaminants
MY202872A (en) 2017-11-20 2024-05-28 Just Evotec Biologics Inc Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
CA3089842A1 (en) 2018-01-29 2019-08-01 Intabio, Inc. Devices, methods and kits for sample characterization
EP3811397B1 (en) 2018-05-31 2024-09-18 Intabio, Llc Methods for interfacing microfluidic systems with mass spectrometry
WO2020055832A1 (en) * 2018-09-10 2020-03-19 Genentech, Inc. Systems and methods for affinity capillary electrophoresis
US11782023B2 (en) * 2018-12-19 2023-10-10 Regeneron Pharmaceuticals, Inc. Ce-western applications for antibody development
CA3126712A1 (en) * 2019-01-31 2020-08-06 Regeneron Pharmaceuticals, Inc. Native microfluidic ce-ms analysis of antibody charge heterogeneity
US12594557B2 (en) 2019-08-12 2026-04-07 Intabio, Llc Isoelectric focusing devices and fixtures
US11285484B2 (en) 2019-08-12 2022-03-29 Intabio, Llc Multichannel isoelectric focusing devices and high voltage power supplies
JP2024513950A (ja) * 2021-04-14 2024-03-27 ディーエイチ テクノロジーズ デベロップメント プライベート リミテッド キャピラリー電気泳動におけるタンパク質分析のための天然蛍光検出
CN118284809A (zh) * 2021-11-25 2024-07-02 豪夫迈·罗氏有限公司 少量抗体副产物的定量
WO2024123698A1 (en) * 2022-12-08 2024-06-13 Regeneron Pharmaceuticals, Inc. Methods to characterizing a fragment crystallizable domain of a bispecific antibody

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP385598A0 (en) * 1998-06-02 1998-06-25 Life Therapeutics Limited Purification of antibodies
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6818112B2 (en) * 1999-04-20 2004-11-16 Target Discovery, Inc. Protein separation via multidimensional electrophoresis
JP4723725B2 (ja) * 1999-04-20 2011-07-13 ターゲット ディスカバリー, インコーポレイテッド 代謝経路を分析するための方法
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
AUPQ743300A0 (en) * 2000-05-11 2000-06-01 Life Therapeutics Limited Separation of avian antibodies
US6927004B2 (en) 2002-03-08 2005-08-09 Asml Netherlands B.V. Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method
WO2007034907A1 (ja) * 2005-09-22 2007-03-29 Chemicals Evaluation And Research Institute 被検化学物質の生物に与える影響の予測方法
EP1803814A1 (en) * 2005-12-27 2007-07-04 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Method of improving the antibody selection capacity in phage-display library
JP5144499B2 (ja) * 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
DK2150617T3 (en) 2007-06-04 2015-01-12 Regeneron Pharma Regions with increased expression and stability
EP3127921A1 (en) * 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
JP4977588B2 (ja) * 2007-12-07 2012-07-18 富士フイルム株式会社 イムノクロマトグラフ方法
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
US9376495B2 (en) * 2011-05-21 2016-06-28 Macrogenics, Inc. Deimmunized serum-binding domains and their use in extending serum half-life
GB2504139B (en) * 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
EP2604624A1 (en) * 2011-12-13 2013-06-19 University College Dublin National University Of Ireland, Dublin Bowman-Birk protease Inhibitor (BBI) binding peptides, and uses thereof in the separation, detection or purification of BBI.
EP3517548A1 (en) * 2012-03-13 2019-07-31 NovImmune S.A. Readily isolated bispecific antibodies with native immunoglobulin format
SG10201609535TA (en) 2012-06-05 2017-01-27 Regeneron Pharma Methods for making fully human bispecific antibodies using a common light chain
TWI864338B (zh) 2012-11-14 2024-12-01 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
CN118271429A (zh) * 2013-08-19 2024-07-02 豪夫迈·罗氏有限公司 用羟基磷灰石层析分离双特异性抗体和双特异性抗体生产副产物
EP3041865A2 (en) * 2013-09-03 2016-07-13 NovImmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions

Similar Documents

Publication Publication Date Title
JP2021152544A5 (cg-RX-API-DMAC7.html)
JP7137663B2 (ja) 多量体タンパク質の純度の決定
JP2021152544A6 (ja) 多量体タンパク質の純度の決定
HRP20201634T1 (hr) Monoklonsko protutijelo protiv interleukina-31
IL275270A (en) Recombinant scavenger cell surface proteins
HRP20200464T1 (hr) Metoda modifikacije polipeptida za pročišćavanje polipeptidnih multimera
Biacchi et al. Analysis of monoclonal antibody by a novel CE‐UV/MALDI‐MS interface
JP2011217747A5 (cg-RX-API-DMAC7.html)
JP2017524725A5 (cg-RX-API-DMAC7.html)
JP2015529201A5 (cg-RX-API-DMAC7.html)
RU2012157727A (ru) Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
EA201891410A1 (ru) Антитела к с5 и способы их применения
JP2024516699A5 (cg-RX-API-DMAC7.html)
JP2015535344A5 (cg-RX-API-DMAC7.html)
JP2018520127A5 (cg-RX-API-DMAC7.html)
CN104697936A (zh) 用于检测生物标志物浓度的生物传感系统及其检测方法
MX2021014171A (es) Metodos para identificar y cuantificar proteinas de la celula huesped.
ES3041610T3 (en) Systems and methods for affinity capillary electrophoresis
TW201144810A (en) Kits for RhD blood type determination and method for RhD blood type determination by using the same
HK40059237A (en) Multimeric protein purity determination
Belsom et al. structure prediction (CASP11)[version 1; referees: 1 approved, 2
UA128977U (uk) Спосіб прогнозування розвитку остеоартрозу
UA128937U (uk) Спосіб прогнозування розвитку остеоартрозу
AR043718A1 (es) Anticuerpos monoclonales que se unen especificamente y con afinidad equivalente a todas las variantes glicosiladas de eritropoyetina recombinante humana, linea celular que los produce y metodo para la deteccion cuantitiva de eritropoyetina humana recombinante
HK1252480B (en) Multimeric protein purity determination